139 related articles for article (PubMed ID: 30794003)
1. Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis.
Hagiwara S; Tsuboi H; Terasaki T; Terasaki M; Toko H; Shimizu M; Honda F; Yagishita M; Ohyama A; Takahashi H; Yokosawa M; Asashima H; Kondo Y; Matsumoto I; Sumida T
Mod Rheumatol; 2020 Mar; 30(2):365-372. PubMed ID: 30794003
[No Abstract] [Full Text] [Related]
2. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics of psoriatic arthritis with positive rheumatoid factor or anti-cyclic citrullinated peptide antibody].
Dai LY; Gong DD; Zhao JX
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):1008-1013. PubMed ID: 31848495
[TBL] [Abstract][Full Text] [Related]
4. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
Shibata S; Tada Y; Komine M; Hattori N; Osame S; Kanda N; Watanabe S; Saeki H; Tamaki K
J Dermatol Sci; 2009 Jan; 53(1):34-9. PubMed ID: 18752933
[TBL] [Abstract][Full Text] [Related]
5. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
6. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis.
Candia L; Marquez J; Gonzalez C; Santos AM; Londoño J; Valle R; Zabaleta J; Yaqub Z; Espinoza LR
J Clin Rheumatol; 2006 Oct; 12(5):226-9. PubMed ID: 17023808
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
8. Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients.
Maejima H; Aki R; Watarai A; Shirai K; Hamada Y; Katsuoka K
J Dermatol; 2010 Apr; 37(4):339-45. PubMed ID: 20507403
[TBL] [Abstract][Full Text] [Related]
9. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.
Inanc N; Dalkilic E; Kamali S; Kasapoglu-Günal E; Elbir Y; Direskeneli H; Inanc M
Clin Rheumatol; 2007 Jan; 26(1):17-23. PubMed ID: 16538391
[TBL] [Abstract][Full Text] [Related]
10. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
[TBL] [Abstract][Full Text] [Related]
11. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
Cuchacovich M; Catalan D; Wainstein E; Gatica H; Soto L; Aravena O; Pesce B; Sabugo F; Aguillón JC
Clin Exp Rheumatol; 2008; 26(6):1067-73. PubMed ID: 19210871
[TBL] [Abstract][Full Text] [Related]
12. Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review.
Popescu C; Zofotă S; Bojincă V; Ionescu R
J Med Life; 2013; 6(4):376-82. PubMed ID: 24701255
[TBL] [Abstract][Full Text] [Related]
13. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
14. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings.
Iannone F; Lopriore S; Bucci R; Lopalco G; Chialà A; Cantarini L; Lapadula G
J Rheumatol; 2016 May; 43(5):911-7. PubMed ID: 26980583
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to cyclic citrullinated peptides in psoriatic arthritis.
Bogliolo L; Alpini C; Caporali R; Scirè CA; Moratti R; Montecucco C
J Rheumatol; 2005 Mar; 32(3):511-5. PubMed ID: 15742445
[TBL] [Abstract][Full Text] [Related]
16. Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?
Perez-Alamino R; Garcia-Valladares I; Cuchacovich R; Iglesias-Gamarra A; Espinoza LR
Rheumatol Int; 2014 Sep; 34(9):1211-6. PubMed ID: 24515446
[TBL] [Abstract][Full Text] [Related]
17. Anti-cyclic citrullinated peptide antibody in psoriatic arthritis: a meta-analysis of its frequency and association with clinical features.
Kim KY; Lee YH
Z Rheumatol; 2020 May; 79(4):397-403. PubMed ID: 31286191
[TBL] [Abstract][Full Text] [Related]
18. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
[TBL] [Abstract][Full Text] [Related]
19. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
[TBL] [Abstract][Full Text] [Related]
20. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
